Mostrar el registro sencillo del ítem

FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

dc.contributor.authorVerger, A.*
dc.contributor.authorYakushev, I.*
dc.contributor.authorAlbert, N.L.*
dc.contributor.authorvan Berckel, B.*
dc.contributor.authorBrendel, M.*
dc.contributor.authorCecchin, D.*
dc.contributor.authorAguiar Fernández, Pablo*
dc.contributor.authorFraioli, F.*
dc.contributor.authorGuedj, E.*
dc.contributor.authorMorbelli, S.*
dc.contributor.authorTolboom, N.*
dc.contributor.authorTraub-Weidinger, T.*
dc.contributor.authorVan Weehaeghe, D.*
dc.contributor.authorBarthel, H.*
dc.date.accessioned2025-09-09T11:22:57Z
dc.date.available2025-09-09T11:22:57Z
dc.date.issued2023
dc.identifier.citationVerger A, Yakushev I, Albert NL, van Berckel B, Brendel M, Cecchin D, et al. FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective. Vol. 50, European Journal of Nuclear Medicine and Molecular Imaging. Springer Science and Business Media Deutschland GmbH; 2023. pp. 1553-5.
dc.identifier.issn1619-7089
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/6416a7b25db420433b7b9fca
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21502
dc.description.sponsorshipOpen Access funding enabled and organized by Projekt DEAL.
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHumans *
dc.subject.meshNeuroimaging *
dc.subject.meshPositron-Emission Tomography *
dc.subject.meshAmyloid *
dc.subject.meshAlzheimer Disease *
dc.subject.meshAmyloid beta-Peptides *
dc.titleFDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective
dc.typeArtigo
dc.authorsophosVerger, A.; Yakushev, I.; Albert, N.L.; van Berckel, B.; Brendel, M.; Cecchin, D.; Fernandez, P.A.; Fraioli, F.; Guedj, E.; Morbelli, S.; Tolboom, N.; Traub-Weidinger, T.; Van Weehaeghe, D.; Barthel, H.
dc.identifier.doi10.1007/s00259-023-06177-5
dc.identifier.sophos6416a7b25db420433b7b9fca
dc.issue.number6
dc.journal.titleEuropean Journal of Nuclear Medicine and Molecular Imaging*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)
dc.page.initial1553
dc.page.final1555
dc.relation.projectIDProjekt DEAL
dc.relation.publisherversionhttps://doi.org/10.1007/s00259-023-06177-5
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS Santiago
dc.subject.keywordIDIS
dc.typefidesArtículo de Opinión (Editorial, Carta, ?)
dc.typesophosArtículo de Opinión
dc.volume.number50


Ficheros en el ítem

Descargar/
Nombre:
1291.pdf
Tamaño:
371.7Kb
Formato:
PDF
Descripción:
Verger A, Yakushev I, Albert NL, van Berckel B, Brendel M, Cecchin D, et al. FDA ...

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 International (CC BY 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International (CC BY 4.0)